PR Newswire Clinical TrialsOriginal article
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Data ReadoutpositiveDCVax-LPositive
AI Analysis
Summary
Northwest Biotherapeutics presented updated Phase III survival data for DCVax-L in glioblastoma at the British Neuro-Oncology Annual Meeting, indicating the original survival extension analysis was likely underestimated based on individual patient level data analysis.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Updated Phase III survival data showing original analysis of survival extension was likely underestimated
Importance:7/10
Sentiment:
0.70
DCVax-LglioblastomaPhase IIIsurvival dataindividual patient level analysis
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 8, 2026 6:42 PM